Sponsor Overview
Explore verified public information about ITM Solucin GmbH's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“In such cases, ITM may provide pre-approval access to an investigational drug under the Expanded Access Program/Managed Access Program (EAP/MAP) if specific conditions are met, including: - The patient has a serious or life-threatening illness and no remaining treatment options. - The patient is ineligible for an ITM clinical trial. - The investigational drug has sufficient clinical data to determine an appropriate dose. - A benefit-risk analysis supports treatment. - Access does not impact clinical trials or regulatory review. - Adequate drug supply is available.”
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.